• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Predictors of sorafenib benefit in patients with hepatocellular carcinoma.

作者信息

Jackson Richard, Psarelli Eftychia, Berhane Sarah, Johnson Philip J

机构信息

Liverpool Cancer Trials Unit, University of Liverpool, Block C, Waterhouse Building, Brownlow Street, Liverpool L69 3GL, United Kingdom.

Department of Molecular and Cancer Medicine, University of Liverpool, Sherrington Building, Ashby Street, Liverpool L69 3GE, United Kingdom.

出版信息

J Hepatol. 2018 Mar;68(3):619-620. doi: 10.1016/j.jhep.2017.09.028. Epub 2017 Oct 24.

DOI:10.1016/j.jhep.2017.09.028
PMID:29079288
Abstract
摘要

相似文献

1
Predictors of sorafenib benefit in patients with hepatocellular carcinoma.索拉非尼对肝细胞癌患者疗效的预测因素。
J Hepatol. 2018 Mar;68(3):619-620. doi: 10.1016/j.jhep.2017.09.028. Epub 2017 Oct 24.
2
Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma".回复：“索拉非尼对肝细胞癌患者疗效的预测因素”
J Hepatol. 2018 Mar;68(3):620-621. doi: 10.1016/j.jhep.2017.10.013. Epub 2017 Oct 24.
3
Response to: Prognostication of HCC patients under sorafenib is not always possible.回应：索拉非尼治疗下的肝癌患者并不总是能够进行预后评估。
Liver Int. 2020 May;40(5):1243-1244. doi: 10.1111/liv.14335. Epub 2020 Jan 3.
4
Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.中性粒细胞与淋巴细胞比值在接受索拉非尼治疗的晚期肝细胞癌患者中的预测作用
Asian Pac J Cancer Prev. 2014;15(2):1063. doi: 10.7314/apjcp.2014.15.2.1063.
5
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.索拉非尼联合经导管动脉化疗栓塞治疗晚期肝细胞癌的疗效增强。
Jpn J Clin Oncol. 2014 Aug;44(8):711-7. doi: 10.1093/jjco/hyu068. Epub 2014 May 22.
6
Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.单药索拉非尼治疗转移性肝细胞癌的持续完全缓解
J Gastrointest Cancer. 2013 Mar;44(1):98-101. doi: 10.1007/s12029-012-9438-6.
7
Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.肝细胞癌：通过肝白血病因子向索拉非尼耐药演变
Gut. 2019 Oct;68(10):1728-1730. doi: 10.1136/gutjnl-2019-318999. Epub 2019 Jul 3.
8
Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?索拉非尼是伴有大血管侵犯或转移性疾病的肝细胞癌的最佳治疗方法吗？
Hepatology. 2018 Aug;68(2):786. doi: 10.1002/hep.29862.
9
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.克服肝细胞癌中索拉非尼治疗耐药性：在治疗模式迅速变化之际的未来展望。
EBioMedicine. 2020 Feb;52:102644. doi: 10.1016/j.ebiom.2020.102644. Epub 2020 Jan 31.
10
[Experience and future prospect of hepatocellular carcinoma treatment by sorafenib].索拉非尼治疗肝细胞癌的经验与未来展望
Nihon Shokakibyo Gakkai Zasshi. 2019;116(1):18-27. doi: 10.11405/nisshoshi.116.18.

引用本文的文献

1
Clinical aspects and treatment of hepatocellular carcinoma in north-eastern Poland.波兰东北部肝细胞癌的临床特征与治疗
Clin Exp Hepatol. 2021 Mar;7(1):79-84. doi: 10.5114/ceh.2021.104631. Epub 2021 Mar 25.
2
Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study.探索性分析以确定从经动脉化疗栓塞术与索拉非尼联合治疗中获益的不可切除肝细胞癌一线治疗候选者：一项多中心回顾性观察研究
Liver Cancer. 2020 Jun;9(3):308-325. doi: 10.1159/000505692. Epub 2020 Feb 19.
3
Identification of Functional MKK3/6 and MEK1/2 Homologs from Echinococcus granulosus and Investigation of Protoscolecidal Activity of Mitogen-Activated Protein Kinase Signaling Pathway Inhibitors and .
棘球蚴 MKK3/6 和 MEK1/2 同源物的鉴定及丝裂原活化蛋白激酶信号通路抑制剂的原头蚴杀伤活性研究
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01043-18. Print 2019 Jan.